Darlifarnib

Darlifarnib (KO-2806) is an orally active farnesyl transferase inhibitor. Darlifarnib inhibits the mTORC1 signaling pathway, thereby enhancing the anti-angiogenic properties of tyrosine kinase inhibitors. When used in combination with anti-VEGFR tyrosine kinase inhibitors, Darlifarnib promotes renal cell carcinoma tumor regression and inhibits tumor neovascularization. Darlifarnib sensitizes renal cell carcinoma tumors that progress after anti-VEGFR TKI treatment.


Cat. No.: EX-A16947	Purity: >98%

	Chemical structure of Darlifarnib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	KO-2806
CAS No.	3065226-39-0
Purity	>98%
Formula	C29H20N6O
Mol Weight	468.5087
State	Solid
Solubility	soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder -20℃, 3 years; 4℃, 2 years; In solvent -20℃, 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Gasendo JG, et al. Farnesyl transferase inhibitor KO-2806 (darlifarnib) enhances the anti-tumor activity of tyrosine kinase inhibitors in RCC. Mol Cancer Ther. Published online March 26, 2026.
CoA	CoA of Darlifarnib

Smiles:	N#CC1=CC(C2=CC(OCC3=CC([C@@]4(C5=CN=CN5C)N)=CC=C3C#N)=CC=C2)=C6C=C4C=CC6=N1


		Search